1
|
Gzik A, Borek B, Chrzanowski J, Jedrzejczak K, Dziegielewski M, Brzezinska J, Nowicka J, Grzybowski MM, Rejczak T, Niedzialek D, Wieczorek G, Olczak J, Golebiowski A, Zaslona Z, Blaszczyk R. Novel orally bioavailable piperidine derivatives as extracellular arginase inhibitors developed by a ring expansion. Eur J Med Chem 2024; 264:116033. [PMID: 38096651 DOI: 10.1016/j.ejmech.2023.116033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2023] [Revised: 11/24/2023] [Accepted: 12/04/2023] [Indexed: 12/30/2023]
Abstract
Arginase is a multifaced enzyme that plays an important role in health and disease being regarded as a therapeutic target for the treatment of various pathological states such as malignancies, asthma, and cardiovascular disease. The discovery of boronic acid-based arginase inhibitors in 1997 revolutionized attempts of medicinal chemistry focused on development of drugs targeting arginase. Unfortunately, these very polar compounds had limitations such as analysis and purification without chromophores, synthetically challenging space, and poor oral bioavailability. Herein, we present a novel class of boronic acid-based arginase inhibitors which are piperidine derivatives exhibiting a different pharmacological profile compared to our drug candidate in cancer immunotherapy -OATD-02 - dual ARG1/2 inhibitor with high intracellular activity. Compounds from this new series show low intracellular activity, hence they can inhibit mainly extracellular arginase, providing different therapeutic space compared to a dual intracellular ARG1/2 inhibitor. The disclosed series showed good inhibitory potential towards arginase enzyme in vitro (IC50 up to 160 nM), favorable pharmacokinetics in animal models, and encouraging preliminary in vitro and in vivo tolerability. Compounds from the new series have moderate-to-high oral bioavailability (up to 66 %) and moderate clearance in vivo. Herein we describe the development and optimization of the synthesis of the new class of boronic acid-based arginase inhibitors via a ring expansion approach starting from the inexpensive chirality source (d-hydroxyproline). This upgraded methodology facilitated a gram-scale delivery of the final compound and eliminated the need for costly and time-consuming chiral resolution.
Collapse
Affiliation(s)
- Anna Gzik
- Molecure S.A., Zwirki i Wigury 101, Warsaw, 02-089, Poland
| | | | | | | | | | | | - Julita Nowicka
- Molecure S.A., Zwirki i Wigury 101, Warsaw, 02-089, Poland
| | | | - Tomasz Rejczak
- Molecure S.A., Zwirki i Wigury 101, Warsaw, 02-089, Poland
| | | | | | - Jacek Olczak
- Molecure S.A., Zwirki i Wigury 101, Warsaw, 02-089, Poland
| | | | | | | |
Collapse
|
2
|
Borek B, Nowicka J, Gzik A, Dziegielewski M, Jedrzejczak K, Brzezinska J, Grzybowski M, Stanczak P, Pomper P, Zagozdzon A, Rejczak T, Matyszewski K, Golebiowski A, Olczak J, Lisiecki K, Tyszkiewicz M, Kania M, Piasecka S, Cabaj A, Dera P, Mulewski K, Chrzanowski J, Kusmirek D, Sobolewska E, Magdycz M, Mucha L, Masnyk M, Golab J, Nowotny M, Nowak E, Napiorkowska-Gromadzka A, Pikul S, Jazwiec R, Dzwonek K, Dobrzanski P, Meyring M, Skowronek K, Iwanowski P, Zaslona Z, Blaszczyk R. Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy. Mol Cancer Ther 2023:718814. [PMID: 36939275 DOI: 10.1158/1535-7163.mct-22-0721] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2022] [Revised: 02/03/2023] [Accepted: 03/14/2023] [Indexed: 03/21/2023]
Abstract
Pharmacological inhibition of the controlling immunity pathway enzymes arginases 1 and 2 (ARG1 and ARG2) is a promising strategy for cancer immunotherapy. Here, we report the discovery and development of OATD-02, an orally bioavailable, potent arginases inhibitor. The unique pharmacological properties of OATD-02 are evidenced by targeting intracellular ARG1 and ARG2, as well as long drug-target residence time, moderate to high volume of distribution, and low clearance which may jointly provide a weapon against arginase-related tumor immunosuppression and ARG2-dependent tumor cell growth. OATD-02 monotherapy had an antitumor effect in multiple tumor models and enhanced an efficacy of the other immunomodulators. Completed non-clinical studies and human pharmacokinetic predictions indicate a feasible therapeutic window and allow for proposing a dose range for the first-in-human clinical study in cancer patients.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Jakub Golab
- Medical University of Warsaw, Warsaw, Poland
| | - Marcin Nowotny
- International Institute of Molecular and Cell Biology, Warsaw, Poland
| | - Elzbieta Nowak
- International Institute of Molecular and Cell Biology, Warsaw, Poland
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Sklepkiewicz P, Dymek BA, Mlacki M, Koralewski R, Mazur M, Nejman-Gryz P, Korur S, Zagozdzon A, Rymaszewska A, von der Thüsen JH, Siwińska AM, Güner NC, Cheda Ł, Paplinska-Goryca M, Proboszcz M, van den Bosch TPP, Górska K, Golab J, Kamiński RM, Krenke R, Golebiowski A, Dzwonek K, Dobrzanski P. Inhibition of CHIT1 as a novel therapeutic approach in idiopathic pulmonary fibrosis. Eur J Pharmacol 2022; 919:174792. [PMID: 35122869 DOI: 10.1016/j.ejphar.2022.174792] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2021] [Revised: 01/25/2022] [Accepted: 01/26/2022] [Indexed: 12/13/2022]
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive and eventually fatal lung disease with a complex etiology. Approved drugs, nintedanib and pirfenidone, modify disease progression, but IPF remains incurable and there is an urgent need for new therapies. We identified chitotriosidase (CHIT1) as new driver of fibrosis in IPF and a novel therapeutic target. We demonstrate that CHIT1 activity and expression are significantly increased in serum (3-fold) and induced sputum (4-fold) from IPF patients. In the lungs CHIT1 is expressed in a distinct subpopulation of profibrotic, disease-specific macrophages, which are only present in patients with ILDs and CHIT1 is one of the defining markers of this fibrosis-associated gene cluster. To define CHIT1 role in fibrosis, we used the therapeutic protocol of the bleomycin-induced pulmonary fibrosis mouse model. We demonstrate that in the context of chitinase induction and the macrophage-specific expression of CHIT1, this model recapitulates lung fibrosis in ILDs. Genetic inactivation of Chit1 attenuated bleomycin-induced fibrosis (decreasing the Ashcroft scoring by 28%) and decreased expression of profibrotic factors in lung tissues. Pharmacological inhibition of chitinases by OATD-01 reduced fibrosis and soluble collagen concentration. OATD-01 exhibited anti-fibrotic activity comparable to pirfenidone resulting in the reduction of the Ashcroft score by 32% and 31%, respectively. These studies provide a preclinical proof-of-concept for the antifibrotic effects of OATD-01 and establish CHIT1 as a potential new therapeutic target for IPF.
Collapse
Affiliation(s)
| | - Barbara A Dymek
- OncoArendi Therapeutics SA, 02-089, Warsaw, Poland; Postgraduate School of Molecular Medicine, Medical University of Warsaw, 02-097, Warsaw, Poland.
| | | | | | | | - Patrycja Nejman-Gryz
- Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, 02-097, Warsaw, Poland
| | - Serdar Korur
- OncoArendi Therapeutics SA, 02-089, Warsaw, Poland
| | | | | | - Jan H von der Thüsen
- Department of Pathology, Erasmus Medical Center, 3015 GD, Rotterdam, the Netherlands
| | | | | | - Łukasz Cheda
- OncoArendi Therapeutics SA, 02-089, Warsaw, Poland
| | - Magdalena Paplinska-Goryca
- Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, 02-097, Warsaw, Poland
| | - Małgorzata Proboszcz
- Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, 02-097, Warsaw, Poland
| | | | - Katarzyna Górska
- Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, 02-097, Warsaw, Poland
| | - Jakub Golab
- Department of Immunology, Medical University of Warsaw, 02-097, Warsaw, Poland
| | | | - Rafał Krenke
- Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, 02-097, Warsaw, Poland
| | | | | | | |
Collapse
|
4
|
Koralewski R, Dymek B, Mazur M, Sklepkiewicz P, Olejniczak S, Czestkowski W, Matyszewski K, Andryianau G, Niedziejko P, Kowalski M, Gruza M, Borek B, Jedrzejczak K, Bartoszewicz A, Pluta E, Rymaszewska A, Kania M, Rejczak T, Piasecka S, Mlacki M, Mazurkiewicz M, Piotrowicz M, Salamon M, Zagozdzon A, Napiorkowska-Gromadzka A, Bartlomiejczak A, Mozga W, Dobrzański P, Dzwonek K, Golab J, Nowotny M, Olczak J, Golebiowski A. Discovery of OATD-01, a First-in-Class Chitinase Inhibitor as Potential New Therapeutics for Idiopathic Pulmonary Fibrosis. J Med Chem 2020; 63:15527-15540. [PMID: 33078933 DOI: 10.1021/acs.jmedchem.0c01179] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Chitotriosidase (CHIT1) and acidic mammalian chitinase (AMCase) are the enzymatically active chitinases that have been implicated in the pathology of chronic lung diseases such as asthma and interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF) and sarcoidosis. The clinical and preclinical data suggest that pharmacological inhibition of CHIT1 might represent a novel therapeutic approach in IPF. Structural modification of an advanced lead molecule 3 led to the identification of compound 9 (OATD-01), a highly active CHIT1 inhibitor with both an excellent PK profile in multiple species and selectivity against a panel of other off-targets. OATD-01 given orally once daily in a range of doses between 30 and 100 mg/kg showed significant antifibrotic efficacy in an animal model of bleomycin-induced pulmonary fibrosis. OATD-01 is the first-in-class CHIT1 inhibitor, currently completed phase 1b of clinical trials, to be a potential treatment for IPF.
Collapse
Affiliation(s)
- Robert Koralewski
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Barbara Dymek
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Marzena Mazur
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Sylwia Olejniczak
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | | | - Gleb Andryianau
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Piotr Niedziejko
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Michal Kowalski
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Mariusz Gruza
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Bartłomiej Borek
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Karol Jedrzejczak
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Elżbieta Pluta
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Magdalena Kania
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Tomasz Rejczak
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Sylwia Piasecka
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Michal Mlacki
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Michał Piotrowicz
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Magdalena Salamon
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | | | - Aneta Bartlomiejczak
- Structural Biology Center, International Institute of Molecular and Cell Biology, Trojdena 4, 02-109 Warsaw, Poland
| | - Witold Mozga
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Paweł Dobrzański
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Karolina Dzwonek
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Jakub Golab
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland.,Department of Immunology, Medical University of Warsaw, Nielubowicza 5, 02-097 Warsaw, Poland
| | - Marcin Nowotny
- Structural Biology Center, International Institute of Molecular and Cell Biology, Trojdena 4, 02-109 Warsaw, Poland
| | - Jacek Olczak
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Adam Golebiowski
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| |
Collapse
|
5
|
Borek B, Gajda T, Golebiowski A, Blaszczyk R. Boronic acid-based arginase inhibitors in cancer immunotherapy. Bioorg Med Chem 2020; 28:115658. [PMID: 32828425 DOI: 10.1016/j.bmc.2020.115658] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2020] [Revised: 06/27/2020] [Accepted: 07/15/2020] [Indexed: 02/08/2023]
Abstract
Arginase is an enzyme that converts l-arginine to l-ornithine and urea in the urea cycle. There are two isoforms of arginase in mammals: ARG-1 and ARG-2. l-Arginine level changes occur in patients with various types of affliction. An overexpression of arginase leads to the depletion of arginine and then to inhibition of the growth of T and NK cells, and in effect to the tumor escape of the immune response. Based on those observations, an inhibition of arginase is proposed as a method to improve anti-tumor immune responses (via an activation and proliferation of T and NK cells). Boronic acid derivatives as arginase inhibitors are leading, potential therapeutic agents for the treatment of several diseases. All these compounds are derived from the original 2-(S)-amino-6-boronohexanoic acid (ABH), the first boronic acid arginase inhibitor proposed by Christianson et al. This article focuses on the review of such sub-class of arginase inhibitors and highlights their SAR and PK properties. It covers molecules published until early 2020, including patent applications.
Collapse
Affiliation(s)
- Bartlomiej Borek
- OncoArendi Therapeutics SA, 101 Żwirki i Wigury St, 02-089 Warsaw, Poland.
| | - Tadeusz Gajda
- Institute of Organic Chemistry, Faculty of Chemistry, Technical University of Lodz, 116 Stefana Żeromskiego St, 90-924 Łódź, Poland
| | - Adam Golebiowski
- OncoArendi Therapeutics SA, 101 Żwirki i Wigury St, 02-089 Warsaw, Poland
| | - Roman Blaszczyk
- OncoArendi Therapeutics SA, 101 Żwirki i Wigury St, 02-089 Warsaw, Poland
| |
Collapse
|
6
|
Andryianau G, Kowalski M, Piotrowicz MC, Rajkiewicz AA, Dymek B, Sklepkiewicz PL, Pluta E, Stefaniak F, Czestkowski W, Olejniczak S, Mazur M, Niedziejko P, Koralewski R, Matyszewski K, Gruza M, Zagozdzon A, Salamon M, Rymaszewska A, Welzer M, Dzwonek K, Golab J, Olczak J, Bartoszewicz A, Golebiowski A. Benzoxazepine-Derived Selective, Orally Bioavailable Inhibitor of Human Acidic Mammalian Chitinase. ACS Med Chem Lett 2020; 11:1228-1235. [PMID: 32551005 DOI: 10.1021/acsmedchemlett.0c00092] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2020] [Accepted: 04/24/2020] [Indexed: 01/06/2023] Open
Abstract
Human acidic mammalian chitinase (hAMCase) is one of two true chitinases in humans, the function of which remains elusive. In addition to the defense against highly antigenic chitin and chitin-containing pathogens in the gastric and intestinal contents, AMCase has been implicated in asthma, allergic inflammation, and ocular pathologies. Potent and selective small-molecule inhibitors of this enzyme have not been identified to date. Here we describe structural modifications of compound OAT-177, a previously developed inhibitor of mouse AMCase, leading to OAT-1441, which displays high activity and selectivity toward hAMCase. Significantly reduced off-target activity toward the human ether-à-go-go-related gene (hERG) and a good pharmacokinetic profile make OAT-1441 a potential candidate for further preclinical development as well as a useful tool compound to study the physiological role of hAMCase.
Collapse
Affiliation(s)
- Gleb Andryianau
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Michal Kowalski
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Adam A. Rajkiewicz
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
- Centre of New Technologies, University of Warsaw, Banacha 2C, 02-097 Warsaw, Poland
| | - Barbara Dymek
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Elzbieta Pluta
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Filip Stefaniak
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
- Laboratory of Bioinformatics and Protein Engineering, International Institute of Molecular and Cell Biology in Warsaw, Ks. Trojdena 4, 02-109 Warsaw, Poland
| | | | - Sylwia Olejniczak
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Marzena Mazur
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Piotr Niedziejko
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Robert Koralewski
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Mariusz Gruza
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Magdalena Salamon
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Mikolaj Welzer
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Karolina Dzwonek
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Jakub Golab
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
- Department of Immunology, Medical University of Warsaw, Nielubowicza 5, 02-097 Warsaw, Poland
| | - Jacek Olczak
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Adam Golebiowski
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
| |
Collapse
|
7
|
Blaszczyk R, Brzezinska J, Dymek B, Stanczak PS, Mazurkiewicz M, Olczak J, Nowicka J, Dzwonek K, Zagozdzon A, Golab J, Golebiowski A. Discovery and Pharmacokinetics of Sulfamides and Guanidines as Potent Human Arginase 1 Inhibitors. ACS Med Chem Lett 2020; 11:433-438. [PMID: 32292546 PMCID: PMC7153016 DOI: 10.1021/acsmedchemlett.9b00508] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2019] [Accepted: 03/12/2020] [Indexed: 12/25/2022] Open
Abstract
We designed and synthesized a series of arginase inhibitors as derivatives of the well-known 2-(S)-amino-6-boronohexanoic acid (ABH) with basic and neutral side chains in the α-position relative to the amino acid group. In an effort to improve the pharmacokinetic profile of literature examples and retain potent enzymatic activity, sulfamido moieties were introduced to generate hydrogen bond interaction with the aspartic acid residue in the arginase active site. The compounds with basic guanidine-containing side chains were even more potent arginase inhibitors. Both groups of compounds, as designed, demonstrated low clearance in their pharmacokinetic profile. The most active inhibitor 15aa showed high nanomolar potency with IC50 = 32 nM toward human arginase 1 and demonstrated low clearance (4.2 mL/min/kg), long t 1/2, and moderate volume of distribution in rat pharmacokinetic studies.
Collapse
Affiliation(s)
- Roman Blaszczyk
- OncoArendi Therapeutics, Zwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Barbara Dymek
- OncoArendi Therapeutics, Zwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | | | - Jacek Olczak
- OncoArendi Therapeutics, Zwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Julita Nowicka
- OncoArendi Therapeutics, Zwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Karolina Dzwonek
- OncoArendi Therapeutics, Zwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Jakub Golab
- Department of Immunology, Medical University of Warsaw, 02-097 Warsaw, Poland
| | - Adam Golebiowski
- OncoArendi Therapeutics, Zwirki i Wigury 101, 02-089 Warsaw, Poland
| |
Collapse
|
8
|
Mazur M, Dymek B, Koralewski R, Sklepkiewicz P, Olejniczak S, Mazurkiewicz M, Piotrowicz M, Salamon M, Jędrzejczak K, Zagozdzon A, Czestkowski W, Matyszewski K, Borek B, Bartoszewicz A, Pluta E, Rymaszewska A, Mozga W, Stefaniak F, Dobrzański P, Dzwonek K, Golab J, Golebiowski A, Olczak J. Development of Dual Chitinase Inhibitors as Potential New Treatment for Respiratory System Diseases. J Med Chem 2019; 62:7126-7145. [PMID: 31291098 DOI: 10.1021/acs.jmedchem.9b00681] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Acidic mammalian chitinase (AMCase) and chitotriosidase-1 (CHIT1) are two enzymatically active proteins produced by mammals capable of cleaving the glycosidic bond in chitin. Based on the clinical findings and animal model studies, involvement of chitinases has been suggested in several respiratory system diseases including asthma, COPD, and idiopathic pulmonary fibrosis. Exploration of structure-activity relationships within the series of 1-(3-amino-1H-1,2,4-triazol-5-yl)-piperidin-4-amines, which was earlier identified as a scaffold of potent AMCase inhibitors, led us to discover highly active dual (i.e., AMCase and CHIT1) inhibitors with very good pharmacokinetic properties. Among them, compound 30 was shown to reduce the total number of cells in bronchoalveolar lavage fluid of mice challenged with house dust mite extract after oral administration (50 mg/kg, qd). In addition, affinity toward the hERG potassium channel of compound 30 was significantly reduced when compared to the earlier reported chitinase inhibitors.
Collapse
Affiliation(s)
- Marzena Mazur
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| | - Barbara Dymek
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| | - Robert Koralewski
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| | - Piotr Sklepkiewicz
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| | - Sylwia Olejniczak
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| | | | - Michał Piotrowicz
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| | - Magdalena Salamon
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| | - Karol Jędrzejczak
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| | | | | | | | - Bartłomiej Borek
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| | | | - Elżbieta Pluta
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| | | | - Witold Mozga
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| | - Filip Stefaniak
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland.,Laboratory of Bioinformatics and Protein Engineering , International Institute of Molecular and Cell Biology in Warsaw , Ks. Trojdena 4 , 02-109 Warsaw , Poland
| | - Paweł Dobrzański
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| | - Karolina Dzwonek
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| | - Jakub Golab
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland.,Department of Immunology , Medical University of Warsaw , Nielubowicza 5 , 02-097 Warsaw , Poland
| | - Adam Golebiowski
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| | - Jacek Olczak
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| |
Collapse
|
9
|
Mazur M, Olczak J, Olejniczak S, Koralewski R, Czestkowski W, Jedrzejczak A, Golab J, Dzwonek K, Dymek B, Sklepkiewicz PL, Zagozdzon A, Noonan T, Mahboubi K, Conway B, Sheeler R, Beckett P, Hungerford WM, Podjarny A, Mitschler A, Cousido-Siah A, Fadel F, Golebiowski A. Targeting Acidic Mammalian chitinase Is Effective in Animal Model of Asthma. J Med Chem 2018; 61:695-710. [PMID: 29283260 DOI: 10.1021/acs.jmedchem.7b01051] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
This article highlights our work toward the identification of a potent, selective, and efficacious acidic mammalian chitinase (AMCase) inhibitor. Rational design, guided by X-ray analysis of several inhibitors bound to human chitotriosidase (hCHIT1), led to the identification of compound 7f as a highly potent AMCase inhibitor (IC50 values of 14 and 19 nM against human and mouse enzyme, respectively) and selective (>150× against mCHIT1) with very good PK properties. This compound dosed once daily at 30 mg/kg po showed significant anti-inflammatory efficacy in HDM-induced allergic airway inflammation in mice, reducing inflammatory cell influx in the BALF and total IgE concentration in plasma, which correlated with decrease of chitinolytic activity. Therapeutic efficacy of compound 7f in the clinically relevant aeroallergen-induced acute asthma model in mice provides a rationale for developing AMCase inhibitor for the treatment of asthma.
Collapse
Affiliation(s)
- Marzena Mazur
- OncoArendi Therapeutics SA , Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Jacek Olczak
- OncoArendi Therapeutics SA , Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Sylwia Olejniczak
- OncoArendi Therapeutics SA , Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Robert Koralewski
- OncoArendi Therapeutics SA , Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Anna Jedrzejczak
- OncoArendi Therapeutics SA , Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Jakub Golab
- OncoArendi Therapeutics SA , Żwirki i Wigury 101, 02-089 Warsaw, Poland.,Department of Immunology, Medical University of Warsaw , 1A Banacha Str., 02-097 Warsaw, Poland
| | - Karolina Dzwonek
- OncoArendi Therapeutics SA , Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Barbara Dymek
- OncoArendi Therapeutics SA , Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | | | - Tom Noonan
- OncoArendi Therapeutics SA , Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Keyvan Mahboubi
- OncoArendi Therapeutics SA , Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Bruce Conway
- OncoArendi Therapeutics SA , Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Ryan Sheeler
- OncoArendi Therapeutics SA , Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Paul Beckett
- The Institute for Pharmaceutical Discovery , Business Drive 23, Branford, Connecticut 06405, United States
| | - William M Hungerford
- The Institute for Pharmaceutical Discovery , Business Drive 23, Branford, Connecticut 06405, United States
| | - Alberto Podjarny
- Department of Integrative Biology, IGBMC, CNRS, INSERM, Université de Strasbourg , 1 Rue Laurent Fries, 67404 Illkirch, France
| | - Andre Mitschler
- Department of Integrative Biology, IGBMC, CNRS, INSERM, Université de Strasbourg , 1 Rue Laurent Fries, 67404 Illkirch, France
| | - Alexandra Cousido-Siah
- Department of Integrative Biology, IGBMC, CNRS, INSERM, Université de Strasbourg , 1 Rue Laurent Fries, 67404 Illkirch, France
| | - Firas Fadel
- Department of Integrative Biology, IGBMC, CNRS, INSERM, Université de Strasbourg , 1 Rue Laurent Fries, 67404 Illkirch, France
| | - Adam Golebiowski
- OncoArendi Therapeutics SA , Żwirki i Wigury 101, 02-089 Warsaw, Poland
| |
Collapse
|
10
|
Stanczak PS, Grzybowski MM, Wolska P, Zdziarska AM, Mazurkiewicz M, Pilanc P, Gieryng A, Kaminska B, Gzik A, Dziegielewski M, Jedrzejczak K, Borek B, Blaszczyk R, Golebiowski A, Dobrzanski P, Dzwonek K. Abstract B003: Development of OAT-1746, a novel arginase 1 and 2 inhibitor for cancer immunotherapy. Mol Cancer Ther 2018. [DOI: 10.1158/1535-7163.targ-17-b003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Depletion of arginine represents an important mechanism of immunosuppression, and high plasma and tumor arginase (ARG) activity has been demonstrated in patients with a wide spectrum of cancers and correlated with a poor prognosis. Low arginine levels inhibit proliferation and activation of cytotoxic T and NK cells. Preclinical and clinical studies show that simultaneous interference with multiple mechanisms of immunosuppression results in a strongly improved antitumor efficacy. In this context, we have developed OAT-1746, a novel, potent, and selective small-molecule inhibitor of ARG1 and ARG2 with profound antitumor efficacy as a monotherapy and in combinations with gemcitabine and PD-L1 inhibitor.
The IC50 of OAT-1746 was determined against the recombinant human and murine ARG1 and ARG2. Cellular activity was evaluated in M2-polarized, bone marrow-derived murine macrophages, and CHO cells transfected with human ARG1 or ARG2. The in vivo antitumor efficacy of OAT-1746 was evaluated in syngeneic mouse models and in an orthotopic C6 rat glioma model after oral administration. In the rat model, C6 glioma cells were implanted by stereotactic intracranial inoculation and the tumor size was measured by bioluminescence in vivo imaging or immunohistochemistry. Quantitative real-time PCR was used to determine inflammatory markers. The tumor arginase activity was assessed using the urea detection assay. L-Arginine and drug levels in plasma and tumor were evaluated by LC/MS method. We have developed potent, selective, orally active inhibitors of ARG1 and ARG2. The clinical candidate, OAT-1746, has IC50=32 nM and 50 nM against human ARG1 and ARG2, respectively, and a potent cellular activity (M2 macrophages IC50=32 nM, CHO-K1 hARG1 IC50=55 nM). In vivo, OAT-1746 showed good pharmacologic properties and demonstrated significant antitumor efficacy as a monotherapy in 4 tumor models: B16 (melanoma), LLC (lung carcinoma), CT26 (CRC), and C6 glioma with TGI=34-53%. The antitumor efficacy correlated with sustained pharmacodynamic (PD) effects: suppression of tumor arginase activity and 3-6 fold increases in plasma and tumor arginine concentrations. Induction of inflammatory markers in tumors confirmed reversal of immunosuppression. Combinations of OAT-1746 with PD-L1 checkpoint inhibitor and gemcitabine showed increased efficacy. Administration of OAT-1746 with anti-PD-L1 antibody resulted in a “controlled” tumor growth with 55% of tumors remaining under 500 mm3 at day 24 versus 36% for PD-L1 monotherapy. Full regression was observed in 20% of the animals treated in combination with gemcitabine in comparison to 0% for monotherapy. OAT-1746 also demonstrated efficacy and PD effects in the orthotopic model of GBM, confirming its ability to cross the blood-brain barrier. Together these results support the clinical development of OAT-1746 for cancer therapy.
Citation Format: Paulina Seweryna Stanczak, Marcin Mikolaj Grzybowski, Paulina Wolska, Anna Maria Zdziarska, Marcin Mazurkiewicz, Paulina Pilanc, Anna Gieryng, Bozena Kaminska, Anna Gzik, Marek Dziegielewski, Karol Jedrzejczak, Bartlomiej Borek, Roman Blaszczyk, Adam Golebiowski, Pawel Dobrzanski, Karolina Dzwonek. Development of OAT-1746, a novel arginase 1 and 2 inhibitor for cancer immunotherapy [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B003.
Collapse
Affiliation(s)
| | | | | | | | | | - Paulina Pilanc
- 2Nencki Institute of Experimental Biology Polish Academy of Sciences, Warsaw, Poland
| | - Anna Gieryng
- 2Nencki Institute of Experimental Biology Polish Academy of Sciences, Warsaw, Poland
| | - Bozena Kaminska
- 2Nencki Institute of Experimental Biology Polish Academy of Sciences, Warsaw, Poland
| | - Anna Gzik
- 1OncoArendi Therapeutics, Warsaw, Poland
| | | | | | | | | | | | | | | |
Collapse
|
11
|
Mazur M, Bartoszewicz A, Dymek B, Salamon M, Andryianau G, Kowalski M, Olejniczak S, Matyszewski K, Pluta E, Borek B, Stefaniak F, Zagozdzon A, Mazurkiewicz M, Koralewski R, Czestkowski W, Piotrowicz M, Niedziejko P, Gruza MM, Dzwonek K, Golebiowski A, Golab J, Olczak J. Discovery of selective, orally bioavailable inhibitor of mouse chitotriosidase. Bioorg Med Chem Lett 2017; 28:310-314. [PMID: 29292229 DOI: 10.1016/j.bmcl.2017.12.047] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2017] [Revised: 12/08/2017] [Accepted: 12/21/2017] [Indexed: 12/17/2022]
Abstract
This article describes our work towards the identification of a potent and selective inhibitor of mouse chitotriosidase (mCHIT1). A series of small molecule inhibitors of mCHIT1 and mAMCase have been developed from early lead compound 1. Examination of synthetized analogues led to discovery of several novel highly potent compounds. Among them compound 9 (OAT-2068) displays a remarkable 143-fold mCHIT1 vs. mAMCase selectivity. To explain the observed SAR molecular docking experiments were performed, which were in line with the experimental data from the enzymatic assays. Inhibitor 9 (OAT-2068) was found to have an excellent pharmacokinetic profile. This, together with high activity and selectivity, makes the compound an ideal and unique tool for studying the role of CHIT1 in biological models.
Collapse
Affiliation(s)
- Marzena Mazur
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Barbara Dymek
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Magdalena Salamon
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Gleb Andryianau
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Michał Kowalski
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Sylwia Olejniczak
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Elżbieta Pluta
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Bartłomiej Borek
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Filip Stefaniak
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland; Laboratory of Bioinformatics and Protein Engineering, International Institute of Molecular and Cell Biology in Warsaw, Ks. Trojdena 4, 02-109 Warsaw, Poland
| | | | | | - Robert Koralewski
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Michał Piotrowicz
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Piotr Niedziejko
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Mariusz M Gruza
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Karolina Dzwonek
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Adam Golebiowski
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Jakub Golab
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland; Department of Immunology, Medical University of Warsaw, Banacha 1a, 02-097 Warsaw, Poland
| | - Jacek Olczak
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| |
Collapse
|
12
|
Stanczak P, Grzybowski M, Wolska P, Zdziarska A, Mazurkiewicz M, Blaszczyk R, Nowicka J, Sosnowska A, Ramji K, Nowis D, Golab J, Golebiowski A, Dobrzanski P, Dzwonek K. Development of OAT-1746, a novel arginase 1 and 2 inhibitor for cancer immunotherapy. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx376.045] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
13
|
Stanczak P, Grzybowski M, Wolska P, Zdziarska A, Mazurkiewicz M, Blaszczyk R, Nowicka J, Sosnowska A, Ramji K, Nowis D, Golab J, Golebiowski A, Dobrzanski P, Dzwonek K. Development of OAT-1746, a novel arginase 1 and 2 inhibitor for cancer immunotherapy. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx376.046] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Golebiowski A, Paul Beckett R, Van Zandt M, Ji MK, Whitehouse D, Ryder TR, Jagdmann E, Andreoli M, Mazur A, Padmanilayam M, Cousido-Siah A, Mitschler A, Ruiz FX, Podjarny A, Schroeter H. 2-Substituted-2-amino-6-boronohexanoic acids as arginase inhibitors. Bioorg Med Chem Lett 2013; 23:2027-30. [DOI: 10.1016/j.bmcl.2013.02.024] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2012] [Revised: 01/26/2013] [Accepted: 02/01/2013] [Indexed: 11/17/2022]
|
15
|
Van Zandt MC, Whitehouse DL, Golebiowski A, Ji MK, Zhang M, Beckett RP, Jagdmann GE, Ryder TR, Sheeler R, Andreoli M, Conway B, Mahboubi K, D’Angelo G, Mitschler A, Cousido-Siah A, Ruiz FX, Howard EI, Podjarny AD, Schroeter H. Discovery of (R)-2-Amino-6-borono-2-(2-(piperidin-1-yl)ethyl)hexanoic Acid and Congeners As Highly Potent Inhibitors of Human Arginases I and II for Treatment of Myocardial Reperfusion Injury. J Med Chem 2013; 56:2568-80. [DOI: 10.1021/jm400014c] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Michael C. Van Zandt
- The Institutes for Pharmaceutical Discovery, LLC, 23 Business Park
Drive, Branford, Connecticut 06405, United States
| | - Darren L. Whitehouse
- The Institutes for Pharmaceutical Discovery, LLC, 23 Business Park
Drive, Branford, Connecticut 06405, United States
| | - Adam Golebiowski
- The Institutes for Pharmaceutical Discovery, LLC, 23 Business Park
Drive, Branford, Connecticut 06405, United States
| | - Min Koo Ji
- The Institutes for Pharmaceutical Discovery, LLC, 23 Business Park
Drive, Branford, Connecticut 06405, United States
| | - Mingbao Zhang
- The Institutes for Pharmaceutical Discovery, LLC, 23 Business Park
Drive, Branford, Connecticut 06405, United States
| | - R. Paul Beckett
- The Institutes for Pharmaceutical Discovery, LLC, 23 Business Park
Drive, Branford, Connecticut 06405, United States
| | - G. Erik Jagdmann
- The Institutes for Pharmaceutical Discovery, LLC, 23 Business Park
Drive, Branford, Connecticut 06405, United States
| | - Todd R. Ryder
- The Institutes for Pharmaceutical Discovery, LLC, 23 Business Park
Drive, Branford, Connecticut 06405, United States
| | - Ryan Sheeler
- The Institutes for Pharmaceutical Discovery, LLC, 23 Business Park
Drive, Branford, Connecticut 06405, United States
| | - Monica Andreoli
- The Institutes for Pharmaceutical Discovery, LLC, 23 Business Park
Drive, Branford, Connecticut 06405, United States
| | - Bruce Conway
- The Institutes for Pharmaceutical Discovery, LLC, 23 Business Park
Drive, Branford, Connecticut 06405, United States
| | - Keyvan Mahboubi
- The Institutes for Pharmaceutical Discovery, LLC, 23 Business Park
Drive, Branford, Connecticut 06405, United States
| | - Gerard D’Angelo
- The Institutes for Pharmaceutical Discovery, LLC, 23 Business Park
Drive, Branford, Connecticut 06405, United States
| | - Andre Mitschler
- Department of Integrative Biology,
IGBMC, CNRS, INSERM, Université de Strasbourg, 1 rue Laurent Fries, 67404 Illkirch, France
| | - Alexandra Cousido-Siah
- Department of Integrative Biology,
IGBMC, CNRS, INSERM, Université de Strasbourg, 1 rue Laurent Fries, 67404 Illkirch, France
| | - Francesc X. Ruiz
- Department of Integrative Biology,
IGBMC, CNRS, INSERM, Université de Strasbourg, 1 rue Laurent Fries, 67404 Illkirch, France
| | - Eduardo I. Howard
- Department of Integrative Biology,
IGBMC, CNRS, INSERM, Université de Strasbourg, 1 rue Laurent Fries, 67404 Illkirch, France
- IFLYSIB, Conicet, UNLP, Calle 59 N° 789, La Plata, Argentina
| | - Alberto D. Podjarny
- Department of Integrative Biology,
IGBMC, CNRS, INSERM, Université de Strasbourg, 1 rue Laurent Fries, 67404 Illkirch, France
| | - Hagen Schroeter
- Mars, Incorporated, 6885
Elm Street, McLean,Virginia 22101, United States
| |
Collapse
|
16
|
Mull ES, Van Zandt M, Golebiowski A, Beckett RP, Sharma PK, Schroeter H. A versatile approach to the regioselective synthesis of diverse (−)-epicatechin-β-d-glucuronides. Tetrahedron Lett 2012. [DOI: 10.1016/j.tetlet.2012.01.054] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
17
|
Djung JF, Mears RJ, Montalbetti CA, Coulter TS, Golebiowski A, Carr AN, Barker O, Greis KD, Zhou S, Dolan E, Davis GF. The synthesis and evaluation of indolylureas as PKCα inhibitors. Bioorg Med Chem 2011; 19:2742-50. [DOI: 10.1016/j.bmc.2011.02.036] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2011] [Revised: 02/17/2011] [Accepted: 02/21/2011] [Indexed: 10/18/2022]
|
18
|
Clark MP, George KM, Bookland RG, Chen J, Laughlin SK, Thakur KD, Lee W, Davis JR, Cabrera EJ, Brugel TA, VanRens JC, Laufersweiler MJ, Maier JA, Sabat MP, Golebiowski A, Easwaran V, Webster ME, De B, Zhang G. Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3). Bioorg Med Chem Lett 2006; 17:1250-3. [PMID: 17189692 DOI: 10.1016/j.bmcl.2006.12.018] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2006] [Revised: 12/02/2006] [Accepted: 12/04/2006] [Indexed: 11/30/2022]
Abstract
A new class of bicyclic pyrrolopyrimidine-based Janus kinase 3 (JAK-3) inhibitors are described. Many of these inhibitors showed low nanomolar activity against JAK-3.
Collapse
Affiliation(s)
- Michael P Clark
- Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason-Montgomery Road, Mason, OH 45040, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Brugel TA, Maier JA, Clark MP, Sabat M, Golebiowski A, Bookland RG, Laufersweiler MJ, Laughlin SK, VanRens JC, De B, Hsieh LC, Mekel MJ, Janusz MJ. Corrigendum to “Development of N-2,4-pyrimidine-N-phenyl-N′-phenyl ureas as inhibitors of tumor necrosis factor alpha (TNF-α) synthesis. Part 1” [Bioorg. Med. Chem. Lett. 16 (2006) 3510–3513]. Bioorg Med Chem Lett 2006. [DOI: 10.1016/j.bmcl.2006.06.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
20
|
Sabat M, Vanrens JC, Clark MP, Brugel TA, Maier J, Bookland RG, Laufersweiler MJ, Laughlin SK, Golebiowski A, De B, Hsieh LC, Walter RL, Mekel MJ, Janusz MJ. The development of novel C-2, C-8, and N-9 trisubstituted purines as inhibitors of TNF-α production. Bioorg Med Chem Lett 2006; 16:4360-5. [PMID: 16750367 DOI: 10.1016/j.bmcl.2006.05.050] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2006] [Revised: 05/15/2006] [Accepted: 05/16/2006] [Indexed: 10/24/2022]
Abstract
A series of C-2, C-8, and N-9 trisubstituted purine based inhibitors of TNF-alpha production are described. The most potent analogs showed low nanomolar activity against LPS-induced TNF-alpha production in a THP-1 cell based assay. The SAR of the series was optimized with the aid of X-ray co-crystal structures of these inhibitors bound with mutated p38 (mp38).
Collapse
Affiliation(s)
- Mark Sabat
- Procter and Gamble Pharmaceuticals, Health Care Research Center, Mason, OH 45040, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Sabat M, Vanrens JC, Brugel TA, Maier J, Laufersweiler MJ, Golebiowski A, De B, Easwaran V, Hsieh LC, Rosegen J, Berberich S, Suchanek E, Janusz MJ. The development of novel 1,2-dihydro-pyrimido[4,5-c]pyridazine based inhibitors of lymphocyte specific kinase (Lck). Bioorg Med Chem Lett 2006; 16:4257-61. [PMID: 16757169 DOI: 10.1016/j.bmcl.2006.05.072] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2006] [Revised: 05/21/2006] [Accepted: 05/22/2006] [Indexed: 11/21/2022]
Abstract
This communication details the synthesis, biological activity, and proposed binding mode of a novel class of tri-cyclic derivatives of 1,2-dihydro-pyrimido[4,5-c]pyridazines 1 and 2. The most potent analogs disclosed showed low nanomolar activity for the inhibition of Lck kinase.
Collapse
Affiliation(s)
- Mark Sabat
- Procter and Gamble Pharmaceuticals, Health Care Research Center, Mason, OH 45040, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Maier JA, Brugel TA, Sabat M, Golebiowski A, Laufersweiler MJ, VanRens JC, Hopkins CR, De B, Hsieh LC, Brown KK, Easwaran V, Janusz MJ. Development of N-4,6-pyrimidine-N-alkyl-N'-phenyl ureas as orally active inhibitors of lymphocyte specific tyrosine kinase. Bioorg Med Chem Lett 2006; 16:3646-50. [PMID: 16682201 DOI: 10.1016/j.bmcl.2006.04.072] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2006] [Revised: 04/21/2006] [Accepted: 04/24/2006] [Indexed: 10/24/2022]
Abstract
A new class of lymphocyte specific tyrosine kinase (lck) inhibitors based on an N-4,6-pyrimidine-N-alkyl-N'-phenyl urea scaffold is described. Many of these compounds showed low-nanomolar inhibition of lck kinase activity as well as IL-2 synthesis from Jurkat cells. One of these analogs, 7i, was shown to be orally efficacious by in vivo testing in a rat adjuvant-induced arthritis study.
Collapse
Affiliation(s)
- Jennifer A Maier
- Procter & Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason-Montgomery Rd. Mason, OH 45040, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Brugel TA, Maier JA, Clark MP, Sabat M, Golebiowski A, Bookland RG, Laufersweiler MJ, Laughlin SK, Vanrens JC, De B, Hsieh LC, Mekel MJ, Janusz MJ. Development of N-2,4-pyrimidine-N-phenyl-N'-phenyl ureas as inhibitors of tumor necrosis factor alpha (TNF-alpha) synthesis. Part 1. Bioorg Med Chem Lett 2006; 16:3510-3. [PMID: 16632356 DOI: 10.1016/j.bmcl.2006.03.095] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2006] [Revised: 03/27/2006] [Accepted: 03/28/2006] [Indexed: 11/25/2022]
Abstract
A new class of tumor necrosis factor alpha (TNF-alpha) synthesis inhibitors based on an N-2,4-pyrimidine-N-phenyl-N'-phenyl urea scaffold is described. Many of these compounds showed low-nanomolar activity against lipopolysaccharide stimulated TNF-alpha production. X-ray co-crystallization studies with mutated p38alpha showed that these trisubstituted ureas interact with the ATP-binding pocket in a pseudo-bicyclic conformation brought about by the presence of an intramolecular hydrogen bonding interaction.
Collapse
Affiliation(s)
- Todd A Brugel
- Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason-Montgomery Rd., Mason, OH 45040, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Brugel TA, Hudlicky T, Clark MP, Golebiowski A, Sabat M, Endoma MAA, Bui V, Adams D, Laufersweiler MJ, Maier JA, Bookland RG, De B. Convergent synthesis of 2,3-bisarylpyrazolones through cyclization of bisacylated pyrazolidines and hydrazines. Tetrahedron Lett 2006. [DOI: 10.1016/j.tetlet.2006.03.063] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
25
|
Maier JA, Brugel TA, Clark MP, Sabat M, Golebiowski A, Bookland RG, Laufersweiler MJ, Laughlin SK, Vanrens JC, De B, Hsieh LC, Brown KK, Juergens K, Walter RL, Janusz MJ. Development of N-2,4-pyrimidine-N-phenyl-N'-alkyl ureas as orally active inhibitors of tumor necrosis factor alpha (TNF-alpha) synthesis. Part 2. Bioorg Med Chem Lett 2006; 16:3514-8. [PMID: 16632350 DOI: 10.1016/j.bmcl.2006.03.096] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2006] [Revised: 03/27/2006] [Accepted: 03/28/2006] [Indexed: 10/24/2022]
Abstract
A new class of tumor necrosis factor alpha (TNF-alpha) synthesis inhibitors based on a N-2,4-pyrimidine-N-phenyl-N'-alkyl urea scaffold is described. Many of these compounds showed low-nanomolar activity against lipopolysaccharide stimulated TNF-alpha production. Two analogs were tested in an in vivo rat iodoacetate model of osteoarthritis and shown to be orally efficacious. X-ray co-crystallization studies with mutated p38alpha showed that these trisubstituted ureas interact with the ATP-binding pocket in a pseudo-bicyclic conformation brought about by the presence of an intramolecular hydrogen bonding interaction.
Collapse
Affiliation(s)
- Jennifer A Maier
- Procter & Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason-Montgomery Rd., Mason, OH 45040, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Sabat M, C. VanRens J, A. Brugel T, Maier J, J. Laufersweiler M, Golebiowski A, Berberich S, De B. Synthesis of Novel Pyrimido[4,5-c]pyridazines and 1,2-Dihydro-3a,7,9,9b-Tetraaza-cyclopenta[a]naphthalen-3-ones as Potent Inhibitors of Lymphocyte Specific Kinase (LCK). HETEROCYCLES 2006. [DOI: 10.3987/com-06-10806] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
27
|
Laughlin SK, Clark MP, Djung JF, Golebiowski A, Brugel TA, Sabat M, Bookland RG, Laufersweiler MJ, VanRens JC, Townes JA, De B, Hsieh LC, Xu SC, Walter RL, Mekel MJ, Janusz MJ. The development of new isoxazolone based inhibitors of tumor necrosis factor-alpha (TNF-α) production. Bioorg Med Chem Lett 2005; 15:2399-403. [PMID: 15837333 DOI: 10.1016/j.bmcl.2005.02.066] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2004] [Revised: 02/18/2005] [Accepted: 02/22/2005] [Indexed: 11/30/2022]
Abstract
4-Aryl-3-pyridyl and 4-aryl-3-pyrimidinyl based tumor necrosis factor-alpha (TNF-alpha) inhibitors, which contain a novel isoxazolone five-membered heterocyclic core are described. Many showed sub-micromolar activity against lipopolysaccharide-induced TNF-alpha production.
Collapse
Affiliation(s)
- Steven K Laughlin
- Health Care Research Center, Procter and Gamble Pharmaceuticals, 8700 Mason-Montgomery Road, Mason, OH 45040, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Golebiowski A, Townes JA, Laufersweiler MJ, Brugel TA, Clark MP, Clark CM, Djung JF, Laughlin SK, Sabat MP, Bookland RG, VanRens JC, De B, Hsieh LC, Janusz MJ, Walter RL, Webster ME, Mekel MJ. The development of monocyclic pyrazolone based cytokine synthesis inhibitors. Bioorg Med Chem Lett 2005; 15:2285-9. [PMID: 15837310 DOI: 10.1016/j.bmcl.2005.03.007] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2004] [Revised: 03/01/2005] [Accepted: 03/03/2005] [Indexed: 11/30/2022]
Abstract
4-Aryl-5-pyrimidyl based cytokine synthesis inhibitors that contain a novel monocyclic, pyrazolone heterocyclic core are described. Many of these inhibitors showed low nanomolar activity against LPS-induced TNF-alpha production. One of the compounds (6e) was found to be efficacious in the rat iodoacetate (RIA) in vivo model of osteoarthritis. The X-ray crystal structure of a pyrazolone inhibitor cocrystallized with mutated p38 (mp38) is presented.
Collapse
Affiliation(s)
- Adam Golebiowski
- Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason-Montgomery Rd, Mason, OH 45040, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Laufersweiler MJ, Brugel TA, Clark MP, Golebiowski A, Bookland RG, Laughlin SK, Sabat MP, Townes JA, VanRens JC, De B, Hsieh LC, Heitmeyer SA, Juergens K, Brown KK, Mekel MJ, Walter RL, Janusz MJ. The development of novel inhibitors of tumor necrosis factor-alpha (TNF-alpha) production based on substituted [5,5]-bicyclic pyrazolones. Bioorg Med Chem Lett 2005; 14:4267-72. [PMID: 15261284 DOI: 10.1016/j.bmcl.2004.06.001] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2004] [Revised: 06/02/2004] [Accepted: 06/02/2004] [Indexed: 11/29/2022]
Abstract
Novel substituted [5,5]-bicyclic pyrzazolones are presented as inhibitors of tumor necrosis factor-alpha (TNF-alpha) production. Many of these compounds show low nanomolar activity against lipopolysaccaride (LPS)-induced TNF-alpha production in THP-1 cells. This class of molecules was co-crystallized with mutated p38, and several analogs showed good oral bioavailability in the rat. Oral activity of these compounds in the rat iodoacetate model for osteoarthritis is discussed.
Collapse
Affiliation(s)
- Matthew J Laufersweiler
- Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason-Montgomery Rd, Mason, OH 45040, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Townes JA, Golebiowski A, Clark MP, Laufersweiler MJ, Brugel TA, Sabat M, Bookland RG, Laughlin SK, VanRens JC, De B, Hsieh LC, Xu SC, Janusz MJ, Walter RL. The development of new bicyclic pyrazole-based cytokine synthesis inhibitors. Bioorg Med Chem Lett 2004; 14:4945-8. [PMID: 15341957 DOI: 10.1016/j.bmcl.2004.07.024] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2004] [Revised: 07/12/2004] [Accepted: 07/12/2004] [Indexed: 10/26/2022]
Abstract
4-Aryl-5-pyrimidyl-based cytokine synthesis inhibitors of TNF-alpha production, which contain a novel bicyclic pyrazole heterocyclic core, are described. Many of these inhibitors showed low nanomolar activity against LPS-induced TNF-alpha production in a THP-1 cell-based assay and against human p38 alpha MAP kinase in an isolated enzyme assay. The X-ray crystal structure of a bicyclic pyrazole inhibitor co-crystallized with mutated p38 (mp38) is presented.
Collapse
Affiliation(s)
- Jennifer A Townes
- Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason-Montgomery Rd, Mason, OH 45040, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Clark MP, Laughlin SK, Laufersweiler MJ, Bookland RG, Brugel TA, Golebiowski A, Sabat MP, Townes JA, VanRens JC, Djung JF, Natchus MG, De B, Hsieh LC, Xu SC, Walter RL, Mekel MJ, Heitmeyer SA, Brown KK, Juergens K, Taiwo YO, Janusz MJ. Development of orally bioavailable bicyclic pyrazolones as inhibitors of tumor necrosis factor-alpha production. J Med Chem 2004; 47:2724-7. [PMID: 15139749 DOI: 10.1021/jm049968m] [Citation(s) in RCA: 110] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
2-Aryl-3-pyrimidinyl based tumor necrosis factor-alpha (TNF-alpha) inhibitors, which contain a novel bicyclic pyrazolone core, are described. Many showed low-nanomolar activity against lipopolysaccharide-induced TNF-alpha production in monocytic cells. Secondary screening data are presented for the pyrimidinyl bicyclic pyrazolones. Several of these analogues showed good oral bioavailability in rat and efficacy in the rat iodoacetate in vivo model.
Collapse
Affiliation(s)
- Michael P Clark
- Health Care Research Center, Procter and Gamble Pharmaceuticals, 8700 Mason-Montgomery Road, Mason, Ohio 45040, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Abstract
Many lead compounds with the potential to progress to viable drug candidates have been identified from libraries during the past two years. There are two key strategies most often employed to find leads from libraries: first, high-throughput biological screening of corporate compound collections; and second, synthesis and screening of project-directed libraries (i.e. target-based libraries). Numerous success stories, including the discovery of several clinical candidates, testify to the utility of chemical library collections as proven sources of new leads for drug development.
Collapse
Affiliation(s)
- Adam Golebiowski
- Procter & Gamble Pharmaceuticals, Health Care Research Center, Mason, OH 45040-8006, USA.
| | | | | |
Collapse
|
33
|
Golebiowski A, Jozwik J, Klopfenstein SR, Colson AO, Grieb AL, Russell AF, Rastogi VL, Diven CF, Portlock DE, Chen JJ. Solid-supported synthesis of putative peptide beta-turn mimetics via Ugi reaction for diketopiperazine formation. J Comb Chem 2002; 4:584-90. [PMID: 12425603 DOI: 10.1021/cc020029u] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The scope and limitations of the solid-supported synthesis of a bicyclic diketopiperazine, an internal, putative peptide beta-turn mimetic, are presented. The 4CC multicomponent Ugi reaction of alpha-N-Boc-diaminopropionic acid resin ester (an amine input), optically active alpha-bromoacid, aldehyde, and isocyanide is the key step in the proposed synthetic protocol. Application of cyclitive cleavage as the final step led to desired products in high purity.
Collapse
Affiliation(s)
- Adam Golebiowski
- Combinatorial Chemistry Group, Health Care Research Center, Procter & Gamble Pharmaceuticals, 8700 Mason-Montgomery Road, P.O. Box 8006, Mason, Ohio 45040-8006, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Johnson CR, Golebiowski A, Steensma DH, Scialdone MA. Enantio- and diastereoselective transformations of cycloheptatriene to sugars and related products. J Org Chem 2002. [DOI: 10.1021/jo00077a049] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
35
|
|
36
|
|
37
|
Johnson CR, Golebiowski A, Steensma DH. Enzymic asymmetrization in organic media: synthesis of unnatural glucose from cycloheptatriene. J Am Chem Soc 2002. [DOI: 10.1021/ja00050a022] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
38
|
|
39
|
Jurczak J, Golebiowski A, Raczko J. Influence of the N-protecting group on the stereochemical course of [4 + 2] cycloaddition of 1-ethoxy-3-[(trimethylsilyl)oxy]buta-1,3-diene to .alpha.-amino aldehydes. J Org Chem 2002. [DOI: 10.1021/jo00272a001] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
40
|
Golebiowski A, Klopfenstein SR, Portlock DE. High-throughput organic synthesis of peptide mimetics. Curr Opin Drug Discov Devel 2001; 4:428-34. [PMID: 11727308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
This article is a subjective review of the literature from 1999 to March 2001. It seeks to highlight current progress in the high-throughput synthesis of peptide mimetics. The review is loosely classified into sections based on the type of secondary structural feature which is being mimicked (reverse turn, beta-strand, peptide surrogates) or a common motif. The examples chosen have demonstrated the ability to produce a large number of compounds rapidly or, in our opinion, the method could produce large numbers of compounds if desired.
Collapse
Affiliation(s)
- A Golebiowski
- Procter & Gamble Pharmaceuticals, Combinatorial Chemistry Section, Mason, OH 45040-8006, USA.
| | | | | |
Collapse
|
41
|
Abstract
Lead compounds with the potential to progress to viable drug candidates have been identified from libraries using several strategies. These include rapid screening of large diverse collections, thematic libraries, project-directed libraries, and three-dimensional molecular models of corporate databases. There have been numerous success stories, including the identification of several clinical candidates.
Collapse
Affiliation(s)
- A Golebiowski
- Procter & Gamble Pharmaceuticals, Health Care Research Center 45040-8006, Mason, OH, USA.
| | | | | |
Collapse
|
42
|
Chen JJ, Golebiowski A, McClenaghan J, Klopfenstein SR, West L. Universal Rink–isonitrile resin: application for the traceless synthesis of 3-acylamino imidazo[1,2- a ]pyridines. Tetrahedron Lett 2001. [DOI: 10.1016/s0040-4039(01)00159-9] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
43
|
Chen JJ, Golebiowski A, Klopfenstein SR, McClenaghan J, Peng SX, Portlock DE, West L. Multi-Component Synthesis of Imidazo[1,2-a] Annulated Heterocycles on α-Isocyano Resin Esters. Synlett 2001. [DOI: 10.1055/s-2001-16059] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
44
|
Abstract
[structure: see text]The solid-supported synthesis of a bicyclic diketopiperazine, a potential peptide beta-turn mimetic, is described. The Ugi reaction between the resin ester of alpha-N-Boc-diaminopropionic acid (an amine input), alpha-bromo acid, aldehyde, and isocyanide is the key step in the proposed protocol.
Collapse
Affiliation(s)
- A Golebiowski
- Procter & Gamble Pharmaceuticals, Combinatorial Chemistry Group, Health Care Research Center, Mason, Ohio 45040-8006, USA.
| | | | | | | | | | | | | |
Collapse
|
45
|
Golebiowski A, Klopfenstein SR, Chen JJ, Shao X. Solid supported high-throughput organic synthesis of peptide β-turn mimetics via tandem Petasis reaction/diketopiperazine formation. Tetrahedron Lett 2000. [DOI: 10.1016/s0040-4039(00)00669-9] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
46
|
Klopfenstein SR, Chen JJ, Golebiowski A, Li M, Peng SX, Shao X. A practical synthesis of peptide mimetics via the solid-phase Petasis reaction. Tetrahedron Lett 2000. [DOI: 10.1016/s0040-4039(00)00668-7] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
47
|
Peng SX, Henson C, Strojnowski MJ, Golebiowski A, Klopfenstein SR. Automated high-throughput liquid-liquid extraction for initial purification of combinatorial libraries. Anal Chem 2000; 72:261-6. [PMID: 10658318 DOI: 10.1021/ac990946v] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
An automated high-throughput liquid-liquid extraction (LLE) methodology has been developed and utilized for the initial purification of the combinatorial library samples containing unreacted amines and other water-soluble byproducts or impurities. Various extraction solvents were evaluated along with different extraction devices. The LLE method was automated using 96-well-format plates and a robotic liquid-handling workstation. In the optimized LLE method, crude combinatorial library samples were dissolved in a water-immiscible organic solvent, butyl acetate, and added to each well in a 96-well-format plate packed with an inert support material coated with hydrochloric acid. Separation occurs based on the partitioning of the compounds between two liquid phases. Product recovery, purity, and amine removal efficiency were determined by HPLC with and without precolumn derivatization. The automated method was successfully applied to the cleanup of some representative combinatorial library samples with greater than 98% amine removal and an average product purity of 90%. The application of the automated high-throughput LLE method should greatly reduce the labor, time, and cost associated with the purification of combinatorial libraries.
Collapse
Affiliation(s)
- S X Peng
- Health Care Research Center, Procter & Gamble Company, Mason, Ohio 45040, USA.
| | | | | | | | | |
Collapse
|
48
|
|
49
|
Johnson CR, Golebiowski A, Schoffers E, Sundram H, Braun MP. Chemoenzymatic Synthesis of Azasugars: D-Talo- and D-Manno-1-Deoxynojirimycin. Synlett 1995. [DOI: 10.1055/s-1995-4967] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
50
|
Johnson CR, Nerurkar BM, Golebiowski A, Sundram H, Esker JL. Chemoenzymatic synthesis of trans-4,5-dihydroxycyclopent-2-enones: conversion to D-1 -deoxynojirimycin. ACTA ACUST UNITED AC 1995. [DOI: 10.1039/c39950001139] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|